Tessier-Lavigne Marc's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Mar 23, 2022
- Accession no.
- 0001708138-22-000027
- Filed
- Mar 23, 2022
- Trade date
- Mar 21, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.13M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tessier-Lavigne MarcCIK 0001437435 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2022 | Common Stock | MOption exerciseAcquired | +7,439 | $380.95 | +$2,833,887.05 | 9,708 | Direct | |
| Mar 21, 2022 | Common Stock | SSaleDisposed | −7,439 | $690.00 | −$5,132,910 | 2,269 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2022 | Common Stock | MOption exerciseDisposed | −7,439 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.